肝复方联合榄香烯注射液介入治疗肝郁脾虚型中晚期原发性肝癌临床研究

Clinical Study of Gan Fu Prescription Combined with Elemene Injection as Interventional Therapy on Liver Stagnation and Spleen Deficiency Type of Middle or Advanced Primary Liver Cancer

目的观察肝复方联合榄香烯注射液经血管介入治疗肝郁脾虚型中晚期原发性肝癌的临床疗效及安全性。方法将60例肝郁脾虚型中晚期原发性肝癌患者随机分为治疗组和对照组各30例,治疗组采用肝复方联合榄香烯注射液经血管介入治疗,对照组单行化疗栓塞治疗。4周为1个疗程,治疗2个疗程。观察比较两组治疗前后的中医临床症状、瘤体大小变化、生活质量及不良反应。结果治疗后两组瘤体疗效相当(P>0.05),但治疗组中医证候疗效、生活质量改善均优于对照组(P<0.05),且治疗组不良反应明显低于对照组(P<0.01)。结论肝复方联合榄香烯注射液介入治疗肝郁脾虚型中晚期原发性肝癌疗效确切,可改善患者临床症状、提高生活质量,安全可行,值得临床推广。

Objective To evaluate the clinical efficacy and adverse reactions of GanFu prescription combined with in-jection as interventional therapy on liver stagnation and spleen deficiency of middle or advanced primary liver cancer. Meth-ods 60 cases of liver stagnation and spleen deficiency type of advanced primary liver cancer patients were randomly divided into treatment group and control group, 30 cases in each group. The treatment group was treated with GanFu Prescription combined with elemene injection as interventional therapy, and the control group was treated with embolism for 2 courses, 4 weeks as one course. The TCM clinical symptoms, the size of tumor, quality of life and adverse reactions before and after treatment in the two groups were observed. Results The effect on tumor in the two groups are equal （P〉0.05）, but the treat-ment group in improving TCM symptoms, life of quality is better than the control group （P〈0.05）. The adverse reaction in treatment group is lower than those in the control group （P〈0.01）. Conclusion The effect of GanFu prescription combined with injection as interventional therapy on liver stagnation and spleen deficiency of middle or advanced primary liver cancer is ob-vious, safe and feasible. It is worthy of the clinical promotion.